skip to Main Content
 

Are Investors still sweet on Tate & Lyle shares?

*

So far this year investors haven’t had any hesitation in buying Tate & Lyle shares.

Opening at £6.59, the stock has been pretty consistent in its gains, before picking up the pace in the last month or so. Tate & Lyle shares PLC now sits at a current trading price, and 2 and a half-year peak, of £7.94.

The company kept things pretty vague in February’s third quarter update. Group adjusted pre-tax profit in constant currency for the 3 months to 31st December may have been ‘ahead of the comparative period’, but no hint was given as to by how much.

Its Food & Beverage Solutions division saw higher adjusted operating profit, with ‘volume growth in line with the first half’, where they rose 4%. Sucralose volumes were higher thanks to a programme to optimise production at its Alabama facility, helping adjusted operating profit sneak ‘slightly ahead’ of last year. The Primary Products arm was the sole part of the business to see adjusted operating profit go in the wrong direction, as weaker demand in North American sweeteners led to lower volumes.

The main takeaway from the details-light Q3 statement was that Tate & Lyle is expecting earnings per share in constant currency growth to be in a mid-single digit range, though ‘towards the lower end’ due to energy and transportation cost inflation and a year of strong commodities performance.

Analysts, meanwhile, are expecting the company to post a slight improvement in adjusted pre-tax profit on Thursday, from £301 million to £303 million year-on-year, with adjusted diluted earnings per share at 51.1p, roughly a 2% increase on 2018. Investors will also want to hear of any acquisitions given that CEO Nick Hampton was talking up the prospect of such at the end of April.

Tate & Lyle shares have a consensus rating of ‘Hold’ alongside an average target price of £7.26.

  • Visit spreadex website

This article is brought to you in association with Spreadex. All opinions expressed in this article are from the author and do not necessarily represent the opinions of The Armchair Trader. You can find out more about Spreadex products and services here, or find more articles from Connor Campbell here.

Like this article? Sign up to our free newsletter.

This article does not constitute investment advice. Do your own research or consult a professional advisor.

The Armchair Trader's 'How to' Guides

In-depth Reports

Detailed reviews of selected companies and investment trusts.

Thanks to our Partners

Our partners are established, regulated businesses and we are grateful for their support.

Aquis
FP Markets
IG
Pepperstone
WisdomTree
CME Group
Back To Top